Literature DB >> 6502313

Decreased response of plasma immunoreactive erythropoietin to "available oxygen" in anemia of prematurity.

M S Brown, J F Garcia, R H Phibbs, P R Dallman.   

Abstract

Erythropoietin, hemoglobin, hematocrit, oxygen affinity (P50), and reticulocyte counts were measured weekly starting at 1 week of age in 10 very-low-birth-weight infants and on a single occasion in 15 healthy men. In the adults, "available oxygen" (derived from oxygen carrying capacity and P50) averaged 13.1 ml/dl blood and the mean erythropoietin level was 15.2 mU/ml. Erythropoietin levels in the infants were inversely related to concentration of hemoglobin, P50, and available oxygen. However, despite the much lower mean "available oxygen" of 9.3 ml/dl in the infants compared with that in adults (P less than 0.001), the mean erythropoietin value of 8.2 mU/ml in the infants was less than in adults (P less than 0.001). Furthermore, the erythropoietin response to decreased "available oxygen" was lowest in the least mature infants. VLBW infants often develop clinical evidence of hypoxia during the anemia of prematurity. The relatively low erythropoietin levels in relation to "available oxygen" are compatible with a decreased erythropoietin response to hypoxia compared with that in adults. Such a difference in response could be a contributing factor to the anemia of prematurity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6502313     DOI: 10.1016/s0022-3476(84)80309-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  15 in total

1.  Serum erythropoietin concentrations in symptomatic infants during the anaemia of prematurity.

Authors:  J Meyer; A Sive; P Jacobs
Journal:  Arch Dis Child       Date:  1992-07       Impact factor: 3.791

2.  How I transfuse red blood cells and platelets to infants with the anemia and thrombocytopenia of prematurity.

Authors:  Ronald G Strauss
Journal:  Transfusion       Date:  2008-01-07       Impact factor: 3.157

3.  Erythropoietin pharmacokinetic/pharmacodynamic analysis suggests higher doses in treating neonatal anemia.

Authors:  Srividya Neelakantan; John A Widness; Robert L Schmidt; Peter Veng-Pedersen
Journal:  Pediatr Int       Date:  2009-02       Impact factor: 1.524

4.  Plasma erythropoietin in newborn lambs.

Authors:  O V Sjaastad; A K Egeli; A K Blom; T Framstad
Journal:  Acta Vet Scand       Date:  2000       Impact factor: 1.695

Review 5.  Human recombinant erythropoietin in the prevention and treatment of anemia of prematurity.

Authors:  Robin K Ohls
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 6.  Anaemia of prematurity: pathophysiology and treatment.

Authors:  Ronald G Strauss
Journal:  Blood Rev       Date:  2010-11       Impact factor: 8.250

7.  IL-1 beta and IL-3-like activity in preterm infants.

Authors:  H Bessler; L Sirota; I Notti; F Dulitzky; M Djaldetti
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

8.  Serum immunoreactive erythropoietin of children in health and disease.

Authors:  K U Eckardt; W Hartmann; U Vetter; F Pohlandt; R Burghardt; A Kurtz
Journal:  Eur J Pediatr       Date:  1990-04       Impact factor: 3.183

9.  Double blind trial of recombinant human erythropoietin in preterm infants.

Authors:  A J Emmerson; H J Coles; C M Stern; T C Pearson
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

10.  Weekly intravenous administration of recombinant human erythropoietin in infants with the anaemia of prematurity.

Authors:  D Beck; E Masserey; M Meyer; A Calame
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.